Aurion Biotech Expands Leadership Team

Aurion Biotech announced the promotions of Andrew Torres, PhD, to Chief Manufacturing Officer and Sterling Chung to Chief Regulatory & Quality Officer. These appointments were made as the company prepares to initiate a US phase 3 clinical trial in the first quarter of 2026.

Aurion Biotech is developing AURN001, an investigational, single-administration, allogeneic cell therapy for corneal endothelial disease.

"I’m proud to announce the promotions of Andrew Torres and Sterling Chung to Aurion Biotech’s executive team, signaling a new phase of growth as we prepare to launch a US Phase 3 clinical trial in the first quarter of 2026 for our groundbreaking cell therapy AURN001," said Arnaud Lacoste, CEO and Chief Scientific Officer of Aurion Biotech. “Andrew and Sterling have considerable experience in pharmaceuticals and biologics development and a unique ability to navigate highly complex regulatory environments. In a field of drug development where manufacturing and quality ecosystems have yet to be built, Andrew and Sterling’s unique skillsets will help Aurion achieve our mission to restore vision to the millions of people with corneal endothelial blindness.”